Role of radiomics as a predictor of disease recurrence in ovarian cancer: a systematic review.
Oncology
Ovarian cancer
Radiogenomics
Radiomics
Recurrence
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
received:
27
10
2023
accepted:
05
04
2024
revised:
04
04
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
aheadofprint
Résumé
Ovarian cancer is associated with high cancer-related mortality rate attributed to late-stage diagnosis, limited treatment options, and frequent disease recurrence. As a result, careful patient selection is important especially in setting of radical surgery. Radiomics is an emerging field in medical imaging, which may help provide vital prognostic evaluation and help patient selection for radical treatment strategies. This systematic review aims to assess the role of radiomics as a predictor of disease recurrence in ovarian cancer. A systematic search was conducted in Medline, EMBASE, and Web of Science databases. Studies meeting inclusion criteria investigating the use of radiomics to predict post-operative recurrence in ovarian cancer were included in our qualitative analysis. Study quality was assessed using the QUADAS-2 and Radiomics Quality Score tools. Six retrospective studies met the inclusion criteria, involving a total of 952 participants. Radiomic-based signatures demonstrated consistent performance in predicting disease recurrence, as evidenced by satisfactory area under the receiver operating characteristic curve values (AUC range 0.77-0.89). Radiomic-based signatures appear to good prognosticators of disease recurrence in ovarian cancer as estimated by AUC. The reviewed studies consistently reported the potential of radiomic features to enhance risk stratification and personalise treatment decisions in this complex cohort of patients. Further research is warranted to address limitations related to feature reliability, workflow heterogeneity, and the need for prospective validation studies.
Identifiants
pubmed: 38744703
doi: 10.1007/s00261-024-04330-8
pii: 10.1007/s00261-024-04330-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-299.
doi: 10.2147/IJWH.S197604
pubmed: 31118829
pmcid: 6500433
Brucks JA. Ovarian cancer. The most lethal gynecologic malignancy. Nurs Clin North Am. 1992;27(4):835-845.
doi: 10.1016/S0029-6465(22)02813-4
pubmed: 1448359
Garzon S, Lagana AS, Casarin J, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118-1129.
doi: 10.21037/gs-20-325
pubmed: 32953627
pmcid: 7475365
Chang LC, Huang CF, Lai MS, Shen LJ, Wu FL, Cheng WF. Prognostic factors in epithelial ovarian cancer: A population-based study. PLoS One. 2018;13(3):e0194993.
doi: 10.1371/journal.pone.0194993
pubmed: 29579127
pmcid: 5868839
Dinca AL, Birla RD, Dinca VG, Marica C, Panaitescu E, Constantinoiu S. Prognostic Factors in Advanced Ovarian Cancer - A Clinical Trial. Chirurgia (Bucur). 2020;115(1):50-62.
doi: 10.21614/chirurgia.115.1.50
pubmed: 32155399
Fernandez-Garza LE, Dominguez-Vigil IG, Garza-Martinez J, Valdez-Aparicio EA, Barrera-Barrera SA, Barrera-Saldana HA. Personalized Medicine in Ovarian Cancer: A Perspective From Mexico. World J Oncol. 2021;12(4):85-92.
doi: 10.14740/wjon1383
pubmed: 34349852
pmcid: 8297048
Rizzo S, Manganaro L, Dolciami M, Gasparri ML, Papadia A, Del Grande F. Computed Tomography Based Radiomics as a Predictor of Survival in Ovarian Cancer Patients: A Systematic Review. Cancers (Basel). 2021;13(3).
doi: 10.3390/cancers13030573
pubmed: 34680377
pmcid: 8700490
Zhou M, Scott J, Chaudhury B, et al. Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches. AJNR Am J Neuroradiol. 2018;39(2):208-216.
doi: 10.3174/ajnr.A5391
pubmed: 28982791
pmcid: 5812810
Tiwari P, Prasanna P, Wolansky L, et al. Computer-Extracted Texture Features to Distinguish Cerebral Radionecrosis from Recurrent Brain Tumors on Multiparametric MRI: A Feasibility Study. AJNR Am J Neuroradiol. 2016;37(12):2231-2236.
doi: 10.3174/ajnr.A4931
pubmed: 27633806
pmcid: 5161689
Pereira S, Pinto A, Alves V, Silva CA. Brain Tumor Segmentation Using Convolutional Neural Networks in MRI Images. IEEE Trans Med Imaging. 2016;35(5):1240-1251.
doi: 10.1109/TMI.2016.2538465
pubmed: 26960222
Shui L, Ren H, Yang X, et al. The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. Front Oncol. 2020;10:570465.
doi: 10.3389/fonc.2020.570465
pubmed: 33575207
Liu Q, Jiang P, Jiang Y, et al. Prediction of Aneurysm Stability Using a Machine Learning Model Based on PyRadiomics-Derived Morphological Features. Stroke. 2019;50(9):2314-2321.
doi: 10.1161/STROKEAHA.119.025777
pubmed: 31288671
Apte AP, Iyer A, Crispin-Ortuzar M, et al. Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys. 2018.
doi: 10.1002/mp.13046
pubmed: 29896896
Ger RB, Cardenas CE, Anderson BM, et al. Guidelines and Experience Using Imaging Biomarker Explorer (IBEX) for Radiomics. J Vis Exp. 2018(131).
doi: 10.3791/57132-v
pubmed: 29364284
pmcid: 5908445
Singh G, Manjila S, Sakla N, et al. Radiomics and radiogenomics in gliomas: a contemporary update. Br J Cancer. 2021;125(5):641-657.
doi: 10.1038/s41416-021-01387-w
pubmed: 33958734
pmcid: 8405677
Mayerhoefer ME, Materka A, Langs G, et al. Introduction to Radiomics. J Nucl Med. 2020;61(4):488-495.
doi: 10.2967/jnumed.118.222893
pubmed: 32060219
pmcid: 9374044
Veeraraghavan H, Vargas HA, Jimenez-Sanchez A, et al. Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers (Basel). 2020;12(11).
doi: 10.3390/cancers12113403
pubmed: 33212885
pmcid: 7698381
Rundo L, Beer L, Escudero Sanchez L, et al. Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Front Oncol. 2022;12:868265.
doi: 10.3389/fonc.2022.868265
pubmed: 35785153
pmcid: 9243357
Meng Y, Sun J, Qu N, Zhang G, Yu T, Piao H. Application of Radiomics for Personalized Treatment of Cancer Patients. Cancer Manag Res. 2019;11:10851-10858.
doi: 10.2147/CMAR.S232473
pubmed: 31920394
pmcid: 6941598
Liu S, Sun W, Yang S, et al. Deep learning radiomic nomogram to predict recurrence in soft tissue sarcoma: a multi-institutional study. Eur Radiol. 2022;32(2):793-805.
doi: 10.1007/s00330-021-08221-0
pubmed: 34448928
Zhu C, Huang H, Liu X, et al. A Clinical-Radiomics Nomogram Based on Computed Tomography for Predicting Risk of Local Recurrence After Radiotherapy in Nasopharyngeal Carcinoma. Front Oncol. 2021;11:637687.
doi: 10.3389/fonc.2021.637687
pubmed: 33816279
pmcid: 8012724
Wu C, Yu S, Zhang Y, Zhu L, Chen S, Liu Y. CT-Based Radiomics Nomogram Improves Risk Stratification and Prediction of Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol. 2022;12:896002.
doi: 10.3389/fonc.2022.896002
pubmed: 35875140
pmcid: 9302642
Nougaret S, McCague C, Tibermacine H, Vargas HA, Rizzo S, Sala E. Radiomics and radiogenomics in ovarian cancer: a literature review. Abdom Radiol (NY). 2021;46(6):2308-2322.
doi: 10.1007/s00261-020-02820-z
pubmed: 33174120
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Covidence systematic review software. Veritas Health Innovation, Melbourne, Australia.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
doi: 10.7326/0003-4819-155-8-201110180-00009
pubmed: 22007046
Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749-762.
doi: 10.1038/nrclinonc.2017.141
pubmed: 28975929
Schiavo JH. PROSPERO: An International Register of Systematic Review Protocols. Med Ref Serv Q. 2019;38(2):171-180.
doi: 10.1080/02763869.2019.1588072
pubmed: 31173570
Chen HZ, Wang XR, Zhao FM, et al. A CT-based radiomics nomogram for predicting early recurrence in patients with high-grade serous ovarian cancer. Eur J Radiol. 2021;145:110018.
doi: 10.1016/j.ejrad.2021.110018
pubmed: 34773830
Li HM, Gong J, Li RM, et al. Development of MRI-Based Radiomics Model to Predict the Risk of Recurrence in Patients With Advanced High-Grade Serous Ovarian Carcinoma. AJR Am J Roentgenol. 2021;217(3):664-675.
doi: 10.2214/AJR.20.23195
pubmed: 34259544
Li C, Wang H, Chen Y, et al. A Nomogram Combining MRI Multisequence Radiomics and Clinical Factors for Predicting Recurrence of High-Grade Serous Ovarian Carcinoma. J Oncol. 2022;2022:1716268.
pubmed: 35571486
pmcid: 9095390
Wei W, Liu Z, Rong Y, et al. A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study. Front Oncol. 2019;9:255.
doi: 10.3389/fonc.2019.00255
pubmed: 31024855
pmcid: 6465630
Wu Y, Jiang W, Fu L, Ren M, Ai H, Wang X. Intra- and peritumoral radiomics for predicting early recurrence in patients with high-grade serous ovarian cancer. Abdom Radiol (NY). 2023;48(2):733-743.
doi: 10.1007/s00261-022-03717-9
pubmed: 36445408
Wang T, Wang H, Wang Y, et al. MR-based radiomics-clinical nomogram in epithelial ovarian tumor prognosis prediction: tumor body texture analysis across various acquisition protocols. J Ovarian Res. 2022;15(1):6.
doi: 10.1186/s13048-021-00941-7
pubmed: 35022079
pmcid: 8753904
Xue C, Yuan J, Lo GG, et al. Radiomics feature reliability assessed by intraclass correlation coefficient: a systematic review. Quant Imaging Med Surg. 2021;11(10):4431-4460.
doi: 10.21037/qims-21-86
pubmed: 34603997
pmcid: 8408801
Wang Q, Li C, Zhang J, et al. Radiomics Models for Predicting Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Radiomics Quality Score Assessment. Cancers (Basel). 2021;13(22).
doi: 10.3390/cancers13225864
pubmed: 35008370
pmcid: 10991626
Li Y, Liu Y, Liang Y, et al. Radiomics can differentiate high-grade glioma from brain metastasis: a systematic review and meta-analysis. Eur Radiol. 2022;32(11):8039-8051.
doi: 10.1007/s00330-022-08828-x
pubmed: 35587827
Di Donato V, Kontopantelis E, Cuccu I, et al. Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2023;33(7):1070-1076.
doi: 10.1136/ijgc-2023-004313
pubmed: 37094971
Panico C, Avesani G, Zormpas-Petridis K, Rundo L, Nero C, Sala E. Radiomics and Radiogenomics of Ovarian Cancer: Implications for Treatment Monitoring and Clinical Management. Radiol Clin North Am. 2023;61(4):749-760.
doi: 10.1016/j.rcl.2023.02.006
pubmed: 37169435
Cui Y, Zhang J, Li Z, et al. A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study. EClinicalMedicine. 2022;46:101348.
doi: 10.1016/j.eclinm.2022.101348
pubmed: 35340629
pmcid: 8943416
Li C, Yin J. Radiomics Nomogram Based on Radiomics Score from Multiregional Diffusion-Weighted MRI and Clinical Factors for Evaluating HER-2 2+ Status of Breast Cancer. Diagnostics (Basel). 2021;11(8).
doi: 10.3390/diagnostics11081491
pubmed: 35054174
pmcid: 11010531
Fournier L, Costaridou L, Bidaut L, et al. Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. Eur Radiol. 2021;31(8):6001-6012.
doi: 10.1007/s00330-020-07598-8
pubmed: 33492473
pmcid: 8270834
Shi L, Zhang Y, Hu J, et al. Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial. Bioengineering (Basel). 2023;10(6).
doi: 10.3390/bioengineering10060634
pubmed: 38247911
pmcid: 10935485
Keek SA, Wesseling FWR, Woodruff HC, et al. A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. Cancers (Basel). 2021;13(13).
doi: 10.3390/cancers13133271
pubmed: 34210048
pmcid: 8269129